

2. Modified Factor VIII cDNA as claimed in claim 1, wherein the B-domain of the wild-type factor VIII cDNA has been deleted.

3. Modified Factor VIII cDNA as claimed in claim 1, wherein said at least one intron is truncated factor IX intron 1.

5. Modified Factor VIII cDNA as claimed in claim 1, wherein said promoter is the human platelet glycoprotein IIb promoter.

6. Modified Factor VIII cDNA as claimed in claim 1, wherein said at least one intron has been inserted into the wild-type factor VIII cDNA at the original positions of intron 1 and intron 13 of the genomic Factor VIII DNA.

7. A process for the production of Factor VIII, comprising:  
culturing a cell line under conditions suitable to produce a polypeptide encoded by the modified Factor VIII cDNA as claimed in claim 1; and  
recovering said polypeptide from the cell culture medium.

8. Process as claimed in claim 7, wherein the production of Factor VIII is stimulated by an inducer.

9. Process as claimed in claim 8, wherein said inducer is phorbol-12-myristate-13-acetate.

Please add the following new claims 10 and 11:

10. Modified Factor VIII cDNA as claimed in claim 1, wherein said hematopoietic cells are platelets.

11. Process as claimed in claim 7, wherein said cell line is HEL or Dami.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com